Klin Farmakol Farm. 2022;36(3):115-117 | DOI: 10.36290/far.2022.019

Lercanidipine overdose

Marek Pecha1, Vladimír Halouzka2, Lukáš Daniš3, Peter Ondra2
1 Ústav farmakologie Fakultní nemocnice Olomouc a Lékařské fakulty Univerzity Palackého v Olomouci
2 Ústav soudního lékařství a medicínského práva Fakultní nemocnice Olomouc a Lékařské fakulty Univerzity Palackého v Olomouci
3 II. interní klinika Fakultní nemocnice Olomouc, Lékařská fakulta Univerzity Palackého v Olomouci

The case report describes a case of poisoning with lercanidipine, a widely prescribed drug from the group of calcium channel blockers. It follows the case of a 31-year-old man who took 90-100 tablets, equivalent to 900-1000 mg, in a suicide attempt. This is the highest administered dose known yet. The patient was given a gastric lavage, administered activated charcoal and Fortrans (macrogol) to speed up drug elimination. Subsequently, CaCl2 was administered while ionized calcium levels were monitored. After 3 days in the ICU, the patient could be transferred to the psychiatric ward and discharged to home care after less than a week.

Keywords: lercanidipine overdose, calcium channel blockers, dihydropyridines.

Accepted: November 3, 2022; Published: November 3, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pecha M, Halouzka V, Daniš L, Ondra P. Lercanidipine overdose. Klin Farmakol Farm. 2022;36(3):115-117. doi: 10.36290/far.2022.019.
Download citation

References

  1. Špác J, Vyskočilová M. Blokátory kalciového kanálu po 50 letech. Klin Farmakol Farm. 2018;32(1):22-26. Go to original source...
  2. Zdroj SÚKL www.sukl.cz/rok-2020.
  3. Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. 2017;8(4):155-165. Go to original source... Go to PubMed...
  4. Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453-61. Go to original source... Go to PubMed...
  5. SPC přípravku Kapidin; available from: https://www.sukl.cz/modules/medication/download.php?file=SPC159484.pdf&type=spc&as=kapidin-spc.
  6. Barchielli M, Dolfini E, Farina P, Leoni B, Targa G, Vinaccia V, Tajana A. Clinical Pharmacokinetics of Lercanidipine. Journal of Cardiovascular Pharmacology, 1997;29:S1-S15. Go to original source...
  7. Nasa P, Singh A, Juneja D, Singh O, Javeri Y. Continuous venovenous hemodiafiltration along with charcoal hemoperfusion for the management of life-threatening lercanidipine and amlodipine overdose. Saudi J Kidney Dis Transpl. 2014;25(6):1255-1258. Go to original source... Go to PubMed...
  8. Hadjipavlou G, Hafeez A, Messer B, Hughes T. Management of lercanidipine overdose with hyperinsulinaemic euglycae­mia therapy: case report. Scand J Trauma Resusc Emerg Med. 2011;19(1):8. Go to original source... Go to PubMed...
  9. Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med. 1990;19(6):649-653. Go to original source... Go to PubMed...
  10. Večeřa R, Ondra P, Jezdinský J, Adamus M. Výplach žaludku při perorální intoxikaci--sporné pohledy na problematiku [Gastric lavage after peroral intoxication--controversial views]. Cas Lek Cesk. 2015;154(4):174-175. Go to PubMed...
  11. Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24(1):195. Go to original source... Go to PubMed...
  12. Cosbey SH, Carson DJ. A fatal case of amlodipine poisoning. J Anal Toxicol. 1997;21(3):221-222. Go to original source... Go to PubMed...
  13. Launiainen T, Ojanperä I. Drug concentrations is post-morten femoral blood compared with therapeutic concentra­tions in plasma. Drug Test Anal. 2014;6(4):308-316. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.